Product Program year 2025 Source: CMS Open Payments

Cimzia

Drug Immunology

NDC 50474-710-79

Open in the dashboard

General payments

$10,458,256

204,316 payments

Research payments

$8,500,833

983 payments

Through program year 2025, $10,458,256 in general payments and $8,500,833 in research payments were reported against Cimzia (Immunology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

14 rows
Year Kind Amount Payments
2025 General $62,878 568
2025 Research $259,696 30
2024 General $823,425 21,930
2024 Research $561,555 27
2023 General $1,759,351 49,250
2023 Research $534,305 37
2022 General $1,470,602 43,348
2022 Research $927,153 63
2021 General $2,154,492 42,001
2021 Research $958,234 267
2020 General $1,164,742 14,071
2020 Research $2,906,468 348
2019 General $3,022,767 33,148
2019 Research $2,353,422 211

Breakdown

Who paid General payments · program years 2019–2025
  1. UCB, Inc. $10,271,336 204,182 payments
  2. Ucb SA $174,240 122 payments
  3. UCB GmBH $7,075 6 payments
  4. UCB Biosciences Inc. $5,605 6 payments
Top recipients General payments · program year 2025
  1. Jane Salmon Rheumatology · New York, NY $20,275 32% · 2 payments
  2. Shanmugapriya Reddy Rheumatology · Riverview, FL $8,143 13% · 7 payments
  3. Rhonda Lambert Rheumatology · San Mateo, CA $4,211 7% · 4 payments
  4. Frankie Pedigo Rheumatology · Shreveport, LA $3,914 6% · 10 payments
  5. Orrin Troum Rheumatology · Santa Monica, CA $3,800 6% · 4 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Rheumatology Internal Medicine $46,668 79% · 171 practitioners
  2. Dermatology $3,747 6% · 39 practitioners
  3. Infectious Disease Internal Medicine $3,300 6% · 1 practitioner
  4. Nurse Practitioner, Family Nurse Practitioner $1,629 3% · 53 practitioners
  5. Physician Assistant $1,598 3% · 69 practitioners

The top 5 of 24 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. New York $20,548 33% · 11 recipients
  2. California $11,101 18% · 41 recipients
  3. Florida $10,128 16% · 90 recipients
  4. Tennessee $4,053 6% · 36 recipients
  5. Louisiana $3,963 6% · 4 recipients

The top 5 of 42 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

26,688

Prescriptions dispensed, refills included

Drug cost

$173,433,670

Paid at the pharmacy, in all

Prescribers

1,370

With 11 or more claims of it

Medicare Part D drugs matched to Cimzia, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Cimzia (2 Pack) Certolizumab Pegol Similar name 1,370 26,688 $173,433,670

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Ricardo Garcia Alemany Rheumatology FL 273 $1,689,659 $154
Elvin Garcia Rheumatology TX 261 $1,704,507 None on record
Dimitrios Fanopoulos Rheumatology WI 124 $766,892 None on record
Jose Aldrich Rheumatology FL 106 $619,044 $159
Samy Metyas Rheumatology CA 94 $629,592 $8,223

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to Cimzia
Billing code Providers Services Paid by Medicare
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0717 958 61,165,045 $220,117,477

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

204,316 general · 983 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record